Company intelligence / Profile preview

Airway Integrated Management Company

US-based

Ownership: Private
Development stage: Other

Overview

Airway Therapeutics is advancing zelpultide alfa (AT-100), an engineered rhSP-D, aiming to reduce inflammation and infection in respiratory/inflammatory diseases. Its lead program addresses bronchopulmonary dysplasia in preterm infants. Early-stage pipeline; clinical results pending.

Therapeutic areas: Pulmonology
Modalities: BiologicRecombinant protein
Industry: Biotech

Partnerships

No major partnerships described in public results; seeking partners to advance pipeline

Beyond the preview

Go deeper on Airway Integrated Management Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Airway Integrated Management Company.

Explore the full profile